```
    (FILE 'HOME' ENTERED AT 09:32:03 ON 30 AUG 2004)

     FILE 'REGISTRY' ENTERED AT 09:32:17 ON 30 AUG 2004
L1          1498 S AGGGACTTTCCGCTGGGGACTTTCC/SQSN
L2             0 L1 AND DENDRITE
L3             0 L1 AND DENDRITIC

     FILE 'CAPLUS' ENTERED AT 09:34:37 ON 30 AUG 2004
L4           198 S L1
L5             0 L4 AND DENDRITE
L6             6 L4 AND DENDRITIC
L7             6 DUP REM L6 (0 DUPLICATES REMOVED)
```

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:511077 CAPLUS
DOCUMENT NUMBER: 139:79112
TITLE: Composition and method for treating viral infection
INVENTOR(S): Morham, Scott; Zavitz, Kenton; Hobden, Adrian
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053332	A2	20030703	WO 2002-US26549	20020820

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-313695P P 20010820
OTHER SOURCE(S): MARPAT 139:79112
AB Methods for inhibiting virus propagation and treating virus infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the cells. The method can be useful in treating infection by viruses that utilize the Tsg101 protein of their host cells for viral budding within and/or out of the cells. The method can be useful in treating infection by viruses that utilize the such treatment a composition comprising a peptide having an amino acid sequence motif PX1X2P and is capable of binding the UEV domain of Tsg101, wherein X1 and X2 are amino acids, and X2 is not R. Preferably, X1 is threonine (T) or serine (S), and X2 is alanine (A). Preferably the peptide is associated with a transporter that is capable of increasing the uptake of the peptide by a mammalian cell by at least 100%, preferably at least 300%.

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:356193 CAPLUS
DOCUMENT NUMBER: 138:367576
TITLE: Vpr protein epitopes, antibodies and polynucleotides for immunotherapy of HIV infection
INVENTOR(S): Nicolette, Charles A.; Walker, Bruce D.
PATENT ASSIGNEE(S): Genzyme Corporation, USA; Massachusetts General Hospital
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037264	A2	20030508	WO 2002-US34688	20021029

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003165517 A1 20030904 US 2002-283618 20021029
PRIORITY APPLN. INFO.: US 2001-345957P P 20011029

AB The present invention provides synthetic compds., antibodies that recognize and bind to these compds., polynucleotides that encode these compds., and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compns. of the invention.

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:154195 CAPLUS
DOCUMENT NUMBER: 138:203654
TITLE: Tsg101 UEV domain-binding epitope of HIV Gag protein and epitope-containing hybrid polypeptides for treating HIV infection
INVENTOR(S): Zavitz, Kenton; Wettstein, Daniel Albert; Morham, Scott; Hobden, Adrian
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015708	A2	20030227	WO 2002-US26417	20020819
WO 2003015708	C1	20030821		
WO 2003015708	A3	20040226		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-313239P P 20010818

AB Methods for inhibiting HIV propagation and treating HIV infection are provided which include administering to cells infected with HIV a compound capable of inhibiting viral budding from the infected host cells. The compound is a Tsg101 UEV domain-binding HIV gag peptide covalently linked to a transporter capable of increasing the uptake of said peptide by a mammalian cell. The transport is selected from the group consisting of penetratins, l-Tat49-57, d-Tat49-57, retro-inverso isomers of l- or d-Tat49-57, L-arginine oligomers, D-arginine oligomers, L-lysine oligomers, d-lysine oligomers, etc. The methods are especially useful in treating HIV infection and in treating and preventing AIDS.

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:816872 CAPLUS
DOCUMENT NUMBER: 135:355016

TITLE: The use of tolerogenic **dendritic** cells for enhancing tolerogenicity in a host and methods for making the same
INVENTOR(S): Robbins, Paul D.; Lu, Lina; Giannoukakis, Nick
PATENT ASSIGNEE(S): University of Pittsburgh of the Commonwealth System of Higher Education, USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083713	A2	20011108	WO 2001-US13661	20010427
WO 2001083713	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002048564	A1	20020425	US 2001-844915	20010427
PRIORITY APPLN. INFO.:			US 2000-200479P P	20000428

AB The present invention relates to a tolerogenic mammalian **dendritic** cells (DCs) and methods for the production of the tolerogenic DCs. In addition, the present invention provides a method for enhancing tolerogenicity in a host comprising administering the tolerogenic mammalian DCs of the present invention to the host. The tolerogenic DCs of the present invention comprise an oligodeoxyribonucleotide (ODN) which has one or more NF-κB binding sites. The tolerogenic DCs of the present invention may further comprise a viral vector, and preferably an adenoviral vector, which does not affect the tolerogenicity of the tolerogenic DCs when present therein. Enhanced tolerogenicity in a host is useful for prolonging foreign graft survival and for treating inflammatory related diseases, such as autoimmune diseases.

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:199192 CAPLUS
DOCUMENT NUMBER: 137:41416
TITLE: Prolongation of cardiac allograft survival using **dendritic** cells treated with NF-κB decoy oligodeoxyribonucleotides
AUTHOR(S): Giannoukakis, Nick; Bonham, C. Andrew; Qian, Shiguang; Zhou, Zhongyou; Peng, Lansha; Harnaha, Jo; Li, Wei; Thomson, Angus W.; Fung, John J.; Robbins, Paul D.; Lu, Lina
CORPORATE SOURCE: Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA, 15261, USA
SOURCE: Molecular Therapy (2000), 1(5, Pt. 1), 430-437
CODEN: MTOHCK; ISSN: 1525-0016
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB **Dendritic** cells (DC) classically promote immune responses but can be manipulated to induce antigen-specific hyporesponsiveness in vitro. The expression of costimulatory mols. (CD40, CD86, CD80) at the DC cell surface correlates with their capacity to induce or suppress immune responses. Expression of these mols. is associated with NF-κB-

dependent transcription of their genes. DC tolerogenicity has been associated with impaired NF-κB-dependent transcription of costimulatory genes as well as NF-κB translocation to the nucleus. In this report, we demonstrate that double-stranded oligodeoxyribonucleotides containing binding sites for NF-κB (NF-κB ODN) are efficiently incorporated by bone marrow-derived DC and specifically inhibit NF-κB-dependent transcription of a reporter gene. Moreover, exposure of DC to the oligonucleotide decoys inhibited lipopolysaccharide (LPS)-induced nitric oxide production, a marker of DC maturation. Treatment of bone marrow-derived DC progenitors with NF-κB ODN selectively suppressed the cell-surface expression of costimulatory mols. without interfering with MHC class I or class II expression. Furthermore, NF-κB ODN DC induced allogeneic donor-specific hyporesponsiveness in mixed leukocyte cultures, and this was associated with inhibition of Th1-type cytokine production Finally, infusion of NF-κB ODN-modified bone marrow-derived DC into allogeneic recipients prior to heart transplantation resulted in significant prolongation of allograft survival in the absence of immunosuppression. Specific interference with NF-κB and other transcriptional pathways involved in immune stimulation in DC using ODN decoy approaches could be one means to promote tolerance induction in organ transplantation. (c) 2000 Academic Press.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:199264 CAPLUS

DOCUMENT NUMBER: 139:30391

TITLE: Prolongation of cardiac allograft survival using **dendritic** cells treated with NF-κB decoy oligodeoxyribonucleotides. [Erratum to document cited in CA137:41416]

AUTHOR(S): Giannoukakis, Nick; Bonham, C. Andrew; Qian, Shiguang; Chen, Zongyou; Peng, Lansha; Harnaha, Jo; Li, Wei; Thomson, Angus W.; Fung, John J.; Robbins, Paul D.; Lu, Lina

CORPORATE SOURCE: Department of Molecular Genetics and Biochemsitry, University of Pittsburgh, Pittsburgh, PA, 15261, USA

SOURCE: Molecular Therapy (2000), 2(3), 298
CODEN: MTOHCK; ISSN: 1525-0016

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB On page 430, the fourth author's name should read "Zongyou Chen" instead of "Zhongyou Zhou".